CalciMedica stock target raised to $9.50 by Singular Research amid new fund
On Monday, Singular Research adjusted its outlook on CalciMedica (NASDAQ:CALC), a biopharmaceutical company, raising the price target to $9.50 from the previous $6.25. The firm sustained its Buy-Venture rating on the stock. This adjustment comes in the wake of new funding that is expected to bolster CalciMedica\'s progress with its highest pipeline priorities. The analyst...